Publications

Key Publications

  1. Dendritic cells for active immunotherapy: optimizing design and manufacture in order to develop commercially and clinically viable products.
    Vaccine. 2007 Sep 27;25 Suppl 2:B47-60. doi: 10.1016/j.vaccine.2007.06.006. Epub 2007 Jun 21.
  2. Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma.
    Clin Cancer Res. 2020 May 15;26(10):2327-2336. doi: 10.1158/1078-0432.CCR-19-2427. Epub 2020 Feb 7.
  3. Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.
    Cancer. 2015 Apr 21;3:14. doi: 10.1186/s40425-015-0055-3. eCollection 2015.
  4. Evaluation of RNA Amplification Methods to Improve DC Immunotherapy Antigen Presentation and Immune Response.
    Mol Ther Nucleic Acids. 2013 May 7;2(5):e91. doi: 10.1038/mtna.2013.18.
  5. Potency of mature CD40L RNA electroporated dendritic cells correlates with IL-12 secretion by tracking multifunctional CD8(+)/CD28(+) cytotoxic T-cell responses in vitro.
    J Immunother. 2011 Jan;34(1):45-57. doi: 10.1097/CJI.0b013e3181fb651a.
  6. Priming of a novel subset of CD28+ rapidly expanding high-avidity effector memory CTL by post maturation electroporation-CD40L dendritic cells is IL-12 dependent.
    J Immunol. 2008 Oct 15;181(8):5296-305. doi: 10.4049/jimmunol.181.8.5296.
  7. Cytokine maturation followed by CD40L mRNA electroporation results in a clinically relevant dendritic cell product capable of inducing a potent proinflammatory CTL response.
    J Immunother. 2008 Oct;31(8):731-41. doi: 10.1097/CJI.0b013e318183db02. 
  8. Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    J Acquir Immune Defic Syndr. 2016 May 1;72(1):31-8. doi: 10.1097/QAI.0000000000000926. Clinical Trial.
  9. Arcelis AGS-004 dendritic cell-based immunotherapy for HIV infection.
    Immunotherapy. 2010 Jul;2(4):467-76. doi: 10.2217/imt.10.28.
  10. Impact of autologous dendritic cell-based immunotherapy (AGS-004) on B- and T-cell subset changes and immune activation in HIV-infected patients receiving antiretroviral therapy.
    J Acquir Immune Defic Syndr. 2013 Dec 1;64(4):345-50. doi: 10.1097/QAI.0b013e3182a4b9ad.
  11. Assessing risk of a short-term antiretroviral therapy discontinuation as a read-out of viral control in immune-based therapy.
    J Med Virol. 2012 Jun;84(6):885-9. doi: 10.1002/jmv.23297. Clinical Trial.
  12. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy.
    Clin Immunol. 2010 Feb;134(2):140-7. doi: 10.1016/j.clim.2009.09.009. Epub 2009 Nov 4. Clinical Trial.
  13. The immunosuppressive properties of the HIV Vpr protein are linked to a single highly conserved residue, R90.
    PLoS One. 2009 Jun 10;4(6):e5853. doi: 10.1371/journal.pone.0005853.

CAR-CIK

  1. Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities. J Clin Invest. 2020 Aug 11;138473. doi: 10.1172/JCI138473.
  2. Donor-derived CD19-targeted T cells in allogeneic transplants. Curr Opin Hematol. 2015 Nov;22(6):497-502.
  3. Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia.  Hum Gene Ther. 2018 May;29(5):602-613.
  4. Redirecting T cells with Chimeric Antigen Receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia.  J Autoimmun. 2017 Dec;85:141-152.
  5. Transposon-Based CAR T Cells in Acute Leukemias: Where are We Going?  Cells. 2020 May 27;9(6):1337.
  6. Acute Myeloid Leukemia Targeting by Chimeric Antigen Receptor T Cells: Bridging the Gap from Preclinical Modeling to Human Studies.  Hum Gene Ther. 2017 Mar;28(3):231-241.
  7. Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches.  Leukemia. 2015 Jan;29(1):1-10.
  8. Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.  Oncotarget. 2016 Aug 9;7(32):51581-51597.
  9. Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy.  Exp Hematol. 2006 Sep;34(9):1219-29.
  10. Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation.  Biol Blood Marrow Transplant. 2017 Dec;23(12):2070-2078.
  11. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study.  Haematologica. 2007 Jul;92(7):952-9.
  12. Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies.  Haematologica. 2007 Mar;92(3):381-8.

sCD83

  1. Soluble CD83 Inhibits T Cell Activation by Binding to the TLR4/MD-2 Complex on CD14+ Monocytes.
    J Immunol. 2017 Mar 15;198(6):2286-2301. doi: 10.4049/jimmunol.1600802. Epub 2017 Feb 13.
  2. Soluble CD83 ameliorates experimental colitis in mice.
    Mucosal Immunol. 2014 Jul;7(4):1006-18. doi: 10.1038/mi.2013.119. Epub 2014 Jan 15. 
  3. Prevention of chronic renal allograft rejection by soluble CD83.
    Transplantation. 2010 Dec 27;90(12):1278-85. doi: 10.1097/TP.0b013e318200005c. 
  4. Induction of kidney allograft tolerance by soluble CD83 associated with prevalence of tolerogenic dendritic cells and indoleamine 2,3-dioxygenase.
    Transplantation. 2010 Dec 27;90(12):1286-93. doi: 10.1097/TP.0b013e3182007bbf. 
  5. Topical application of soluble CD83 induces IDO-mediated immune modulation, increases Foxp3+ T cells, and prolongs allogeneic corneal graft survival.
    J Immunol. 2013 Aug 15;191(4):1965-75. doi: 10.4049/jimmunol.1201531. Epub 2013 Jul 12. 
  6. Immunosuppression involving soluble CD83 induces tolerogenic dendritic cells that prevent cardiac allograft rejection.
    Transplantation. 2010 Dec 15;90(11):1145-56. doi: 10.1097/TP.0b013e3181f95718. 
  7. Structural identification of recombinant human CD83 mutant variant as a potent therapeutic protein.
    Protein Expr Purif. 2010 Oct;73(2):140-6. doi: 10.1016/j.pep.2010.05.016. Epub 2010 Jun 8.